2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

201. Granulocytes, Monocytes, and Macrophages: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Bioinformatics, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Multi-Systemic Interactions, Diseases, Genetic Disorders, Immunology, Autoimmune Disorders, Neutropenia, White Blood Cell Disorders, Infectious Diseases, Viral, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, CLL, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult
PAPER

2966 Multiscale transcriptomic and network-perturbation analyses define a Macrophage–Cytotoxic HLH-like inflammatory ecosystem in DLBCL

Luocheng Zhang, Yang Dai, PhD2, Yushu Zhong, MD3, Xinzhu Tang, N/A4, Yushuang Xiao5, Xu Sun, PhD6, Yijun Wu, MD7, Ailin Zhao, PhD8, Ting Niu9
1 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
2 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
3 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
4 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
5 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
6 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
7 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
8 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
9 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Aim: Diffuse large B-cell lymphoma-associated hemophagocytic lymphohistiocytosis (DLBCL-HLH) represents a therapeutically challenging condition, yet the cellular interactions and molecular circuits responsible for this inflammatory state remain undefined. We aimed to uncover a macrophage-driven MAS/HLH-like inflammatory ecosystem in DLBCL by delineating its cellular architecture, regulatory hierarchy, and spatial organization.

 

Methods: Single-cell transcriptomic datasets from DLBCL, low grade follicular lymphoma, and Tonsillitis specimens (GSE182434) were analyzed to define MAS/HLH-like inflammatory programs. A 47-gene MAS/HLH signature was scored at the single-cell level to quantify inflammatory burden. Macrophage and cytotoxic CD8/NK-cell populations were independently reclustered, followed by evaluation of interferon, STAT3-associated, and immune functional programs. Single-cell virtual perturbation modeling was performed to identify regulators of the inflammatory macrophage state. An integrated macrophage-associated IFN/CXCL–HLH-like inflammatory ecosystem (HIE) score was developed and spatially validated using GeoMx transcriptomic data (GSE232853), followed by validation in independent bulk DLBCL cohorts (GSE181063 and GSE117556).

 

Results: MAS/HLH-like inflammatory burden was significantly elevated in DLBCL compared with follicular lymphoma (P = 0.014). High-burden cells were enriched in macrophage-lineage and cytotoxic CD8/NK compartments, with strong correlations between inflammatory burden, macrophage abundance, and cytotoxic clusters (Spearman ρ = 0.812 and 0.762, respectively).

Macrophage reclustering identified an interferon-responsive subcluster characterized by CXCL9, CXCL10, IDO1, STAT1, IRF1, and SIGLEC1 expression. These macrophages showed increased glycolytic activity (P = 2.06 × 10?7), elevated STAT3-associated programs (P = 5.22 × 10?7), and reduced HLA-DR/MHC-II activity (P = 6.86 × 10?²°). Cytotoxic reclustering identified CXCR3-positive, IFNG-expressing CD8/NK states with effector and inhibitory receptor programs. Together, these coordinated macrophage and cytotoxic lymphocyte states defined a macrophage-associated IFN/CXCL–HLH-like inflammatory ecosystem (HIE).

 

Virtual perturbation revealed distinct regulatory programs: IRF1 overexpression enriched NK cell–mediated cytotoxicity and cytokine–cytokine receptor interaction pathways (BH-adjusted P = 0.0285 and 0.0323), whereas STAT3 overexpression induced macrophage remodeling genes and lysosome pathway enrichment (BH-adjusted P = 0.0261). CXCL9 perturbation alone produced no significant transcriptional changes.

 

Spatial validation across 578 GeoMx regions demonstrated enrichment of the inflammatory signature in CD68-segmented DLBCL regions, with 46/58 top-decile regions belonging to this compartment (OR = 19.35; P = 2.87 × 10?²²). The HIE score was reproduced in external bulk cohorts (GSE181063 and REMoDL-B) and showed minimal correlation with macrophage-core abundance.

 

Conclusions: We define a distinct MAS/HLH-like inflammatory ecosystem in DLBCL driven by CXCL9/CXCL10-producing macrophages and IFNG/CXCR3-positive cytotoxic lymphocytes. IRF1- and STAT3-dependent regulatory programs underlie this inflammatory yet immunosuppressive macrophage state. Spatial and cohort validation demonstrate that this axis is biologically distinct from molecular high-grade features, highlighting its potential as a biomarker and therapeutic target.

Luocheng Zhang: No relevant conflicts of interest to declare.